S&P 500 Industrials Sector SEC Filings — March 06, 2026

06-03-2026

Seaboard Corporation's DEF 14A proxy statement solicits votes for its 2026 Annual Meeting on April 20, 2026, at 8:30 a.m. local time at the DoubleTree Hotel in Overland Park, Kansas, to elect five directors until 2027, approve on an advisory basis the compensation of Named Executive Officers, and ratify KPMG LLP as independent auditors for the fiscal year ending December 31, 2026. The record date is February 19, 2026, with 957,794 shares of common stock outstanding, requiring a quorum of 478,898 shares. Principal stockholder Ellen S. Bresky beneficially owns 714,040.24 shares or 74.5%, primarily through Seaboard Flour LLC (358,068.69 shares, 37.4%) and SFC Preferred, LLC (346,155.55 shares, 36.1%).

• ·Annual Meeting location: DoubleTree Hotel, 10100 College Boulevard, Overland Park, Kansas 66210.
• ·Voting on director election requires plurality of votes cast; withhold and broker non-votes have no effect.
• ·Advisory vote on NEO compensation and auditor ratification each require majority of shares present and voting; abstentions treated as against.
• ·Proxy materials available at https://www.seaboardcorp.com/investors.
• ·Company address: 9000 West 67th Street, Merriam, Kansas 66202.

06-03-2026

PMV Pharmaceuticals reported FY2025 net loss of $77.7M, a 32% increase from $58.7M in FY2024, driven by R&D expenses rising 19% to $69.9M amid rezatapopt advancement, while G&A expenses fell 39% to $16.3M; cash and equivalents dropped to $112.9M from $183.3M, with net cash used in operations up to $73.6M from $51.3M, providing runway into Q2 2027. Clinical highlights include on-track PYNNACLE Phase 2 enrollment, FDA Orphan Drug Designation for rezatapopt in TP53 Y220C ovarian cancer, NEJM publication of Phase 1 data, and planned NDA submission in Q1 2027, supported by Phase 2 data showing 34% ORR across cohorts and up to 50% in ovarian cancer. However, cash burn acceleration highlights financial pressures despite promising trial progress.

• ·Median duration of response 7.6 months across all cohorts; 8.0 months in ovarian cancer cohort.
• ·Most frequent TRAEs (>15%): nausea, fatigue, blood creatinine increased, ALT increased (mostly Grade 1-2).
• ·FDA Orphan Drug Designation granted March 2, 2026 for rezatapopt in TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancer.
• ·Phase 1 PYNNACLE results published in New England Journal of Medicine.
• ·Updated ovarian cancer ORR data presented at 2026 European Society of Gynecologic Oncology Congress.

06-03-2026

Solitron Devices, Inc. (SODI) has issued a proxy statement for its 2025 Annual Meeting on April 24, 2026, seeking stockholder approval for the re-election of Charles M. Gillman as Class III director for a term until the 2028 Annual Meeting, ratification of Whitley Penn LLP as independent auditors for the fiscal year ending February 28, 2026, and a non-binding advisory vote on named executive officer compensation. The record date is February 27, 2026, with 2,147,703 shares of common stock outstanding entitling holders to vote. The Board consists of five directors divided into three staggered classes, with no financial performance metrics or period comparisons disclosed in the filing.

• ·Annual Meeting time: 10:00 a.m. Eastern Time at 901 Sansburys Way, West Palm Beach, Florida 33411
• ·Proxy materials mailing date: on or about March 10, 2026
• ·Fiscal year reference: ended February 28, 2025 (10-K available)
• ·Voting quorum: majority of issued and outstanding shares present in person or by proxy
• ·Majority voting standard for uncontested director elections with contingent resignation provision
• ·Committee memberships: Audit (Dwight P. Aubrey, John F. Chiste); Compensation (Dwight P. Aubrey, David W. Pointer, Charles M. Gillman); Nominating (John F. Chiste, David W. Pointer, Charles M. Gillman)

06-03-2026

FIRST Community Bankshares Inc. reported net income of $48.8 million for 2025, down 5.45% from $51.6 million in 2024, with ROA declining to 1.52% from 1.60% and ROE to 9.64% from 10.03%; net interest income FTE fell slightly to $125.1 million while NIM remained nearly flat at 4.42% (down 0.02 percentage points). However, noninterest income rose 8.88% to an unspecified amount driven by service charges, credit quality improved with non-performing loans at 0.61% (down 0.22 percentage points) and lower net charge-offs, and adjusted net income declined modestly by 2.34% to $51.1 million. Noninterest expenses increased 8.01% due to higher salaries, merger costs for the Hometown acquisition (completed January 23, 2026), and other expenses.

• ·Merger-related expenses of $2.91 million in 2025 associated with Hometown acquisition completed January 23, 2026.
• ·Salaries and employee benefits increased $4.73 million YoY.
• ·Book value per share $27.30 on Dec 31, 2025, down $1.43 from 2024 due to special dividends totaling $3.07 per share.
• ·Average loans $2.35B in 2025 vs $2.48B in 2024.
• ·Loan-to-deposit ratio 88.81% on Dec 31, 2025.
• ·Return on average tangible common equity 13.92% for 2025.

06-03-2026

Amphastar Pharmaceuticals, Inc. entered into new executive employment agreements effective March 3, 2026, with existing executives Jacob Liawatidewi (EVP of Corporate Administration Center, Secretary, and board member) at an annual base salary of $525,800 and target bonus of 55% of base, and Rong Zhou (Senior EVP of Production Center) at $590,000 base and 53% target bonus. Agreements provide for 1-year initial terms with auto-renewal, at-will termination, and severance of 2x (highest base + average of prior two years' bonuses) plus 12 months health benefits and full equity vesting acceleration upon qualifying termination; enhanced severance applies post-change in control. No performance metrics or financial impacts from the agreements are disclosed.

• ·90 days advance notice required for non-renewal of agreements.
• ·Severance conditioned on execution of release; includes prorated bonus and prior year accrued bonus on certain terminations.
• ·100% equity vesting acceleration immediately prior to change in control.
• ·Section 280G parachute payment provisions to maximize after-tax benefits.

06-03-2026

Genco Shipping & Trading Ltd filed a DEFA14A on March 6, 2026, disclosing participants in the proxy solicitation for the 2026 Annual Meeting of Shareholders, including independent directors Paramita Das, Kathleen C. Haines, Basil G. Mavroleon, Karin Y. Orsel, Arthur L. Regan, and executives John C. Wobensmith, Peter Allen, Joseph Adamo, Jesper Christensen. The filing urges shareholders to review the upcoming definitive proxy statement on Schedule 14A, white proxy card, and related SEC documents available free on SEC.gov and the company's investor relations site at https://investors.gencoshipping.com/. It references the prior 2025 proxy statement filed April 9, 2025, and multiple Form 4 filings detailing participants' changes in security ownership from May 2025 to February 2026.

• ·Prior proxy statement for 2025 Annual Meeting filed with SEC on April 9, 2025.
• ·Form 4 filings for participants: May 22, 2025; June 3, 2025; August 26, 2025; September 10, 2025; September 15, 2025; November 12, 2025; November 26, 2025; February 18, 2026; February 23, 2026.
• ·Investor contact: Peter Allen, (646) 443-8550; Media contact: Leon Berman, (212) 477-8438, lberman@igbir.com.

06-03-2026

Golden Entertainment, Inc. filed a DEFM14A proxy statement seeking shareholder approval for the F Reorganization, taxable Distribution, and tax-free Merger under Section 368(a), part of the Master Transaction Agreement to separate real estate assets (PropCo) and operations (OpCo), with completion expected in mid-2026 subject to gaming approvals and other conditions. The transactions aim to unlock real estate value highlighted as undervalued since May 2024, with preliminary sale-leaseback indications from VICI, Party A, and Party B ranging $941.2M to $1.0968B at cap rates of 7.5%-8.5%; however, prior outreach to multiple parties yielded no other actionable proposals, and Mr. Sartini (CEO/Chairman) has differing interests via control of OpCo Buyer.

• ·Filing date: March 06, 2026
• ·Special Meeting to approve Transactions; results filed within 4 business days
• ·Conditions include gaming and liquor law approvals, tax opinions for Merger as Section 368(a) reorganization
• ·Preliminary multiples: 11.77x-12.50x (VICI April 10), 12.12x-12.90x (VICI April 16), 11.76x (Party B), 12.58x (Party A), 13.33x (Golden proposed)
• ·Party A structure proposed non-pro rata spinoff (Sartini family 5% OpCo, public 95%)

06-03-2026

Johnson Controls International plc held its Annual General Meeting (AGM) on March 4, 2026, with 556,390,065 ordinary shares represented, approving all proposals including the election of 11 directors to the Board (reduced from 12 after Patrick Decker opted not to stand for reelection), ratification of PricewaterhouseCoopers LLP as independent auditors, authorization for market purchases of company shares, and Board authority to allot shares up to a nominal value of US$1,286,103 (approximately 20% of issued ordinary share capital). All director nominees received strong support, with FOR votes ranging from 487 million (Jean Blackwell) to 515 million (Joakim Weidemanis), alongside approvals for executive compensation advisory vote and waiver of pre-emption rights. No proposals failed, reflecting broad shareholder alignment.

• ·Proposal 2.a (auditor ratification): 520,720,132 FOR, 35,018,103 AGAINST, 651,830 ABSTAIN
• ·Proposal 2.b (auditor remuneration): 543,530,855 FOR, 12,401,799 AGAINST, 457,411 ABSTAIN
• ·Proposal 3 (share repurchases): 553,051,315 FOR, 1,647,206 AGAINST, 1,691,544 ABSTAIN
• ·Proposal 4 (treasury share re-allotment): 551,864,210 FOR, 2,736,338 AGAINST, 1,789,517 ABSTAIN
• ·Proposal 5 (executive compensation): 486,785,469 FOR, 31,871,518 AGAINST, 1,295,508 ABSTAIN

06-03-2026

On March 4, 2026, Alphabet's Leadership Development, Inclusion and Compensation Committee approved a new triennial equity compensation package for CEO Sundar Pichai, recognizing his strong performance, including unchanged on-target values for $126M in PSUs and $84M in GSUs from the 2022 award, plus $130M target Waymo BPUs and $45M target Wing BPUs tied to Other Bets performance. However, his annual salary remains flat at $2M (unchanged since 2020) with no eligibility for an annual bonus. All awards are performance-based with potential 0-200% vesting ranges relative to targets, subject to TSR, unit value growth, and continued employment.

• ·PSUs vest based on Alphabet TSR vs. S&P 100 over 2026-2027 (tranche 1) and 2026-2028 (tranche 2).
• ·GSUs vest 1/12th on March 25, 2026, then 1/36th monthly through January 1, 2029.
• ·Waymo/Wing BPUs vest after 3-year period based on per-unit value increase (0-200%), settling in Common Units.
• ·Award agreements to be filed in 10-Q for quarter ending March 31, 2026.
• ·Upon death, unvested GSUs accelerate; performance equity vests at target.

06-03-2026

06-03-2026

Granite Ridge Resources reported revenues of $450.3M for 2025, up 18% YoY from $380.0M, driven by strong production growth of 28% to 11.7 MBo e with oil volumes up 31% and net producing wells up 21% to 245. However, lower average oil prices ($61.63/Bbl, down 16% YoY) and higher lease operating expenses per Boe ($7.27, up 16%) contributed to a 22% decline in net operating income to $46.4M and impairments rising to $44.7M; net income rose 30% YoY to $24.4M but was down 70% from 2023 levels amid increased debt to $385M.

• ·Net cash used in investing activities increased to $410M in 2025 from $311M in 2024 due to higher capex.
• ·Long-term debt rose to $368M at Dec 31 2025 from $205M at Dec 31 2024.
• ·Retained earnings turned negative at -$17.3M at Dec 31 2025 after $57.7M dividend declaration.
• ·Equity investments declined to $11M current + $0 long-term at Dec 31 2025 from $32M + $0.
• ·Common stock dividend declared at $0.44 per share for 2025.

06-03-2026

Canadian Imperial Bank of Commerce (CIBC) filed a Form F-3 registration statement with the SEC on March 5, 2026, to register up to $20 billion in senior debt securities for potential sale on a delayed or continuous basis pursuant to Rule 415, with specific terms to be detailed in future prospectus supplements. The filing highlights risks including geopolitical tensions, regulatory changes, and cyber threats, but provides no current financial performance metrics or period-over-period comparisons. Securities are not insured by CDIC or FDIC and may be subject to bail-in conversion under Canadian law.

• ·Registrant address: 81 Bay Street, CIBC Square, Toronto, Ontario, Canada M5J 0E7
• ·U.S. agent for service: 300 Madison Avenue, 6th Floor, New York, New York 10017
• ·Securities may be bail-inable under subsection 39.2(2.3) of the CDIC Act

06-03-2026

On March 5, 2026, Liberty Broadband Corporation announced that Renee L. Wilm will transition from her role as Chief Legal Officer and Chief Administrative Officer to Senior Advisor, effective later this year. In her new role, Ms. Wilm will continue providing strategic guidance and counsel to the leadership team while supporting key initiatives. No other changes or financial impacts were disclosed.

• ·Announcement made by Liberty Media Corporation.
• ·Transition effective later in 2026.

06-03-2026

Dave Inc. priced a $175 million (upsized from $150 million) offering of 0% Convertible Senior Notes due 2031, expecting $168 million in net proceeds (or $192.1 million if the $25 million option is exercised fully), to be used for $15.1 million in capped call transactions, $70.5 million to repurchase 334,000 shares, and general corporate purposes including additional repurchases. The notes feature an initial conversion price of $279.13 per share (32.5% premium over $210.67 closing price on March 4, 2026) and a capped call cap price of $421.34 (100% premium). No performance declines noted, but capped calls aim to mitigate dilution risks from potential conversions.

• ·Offering expected to close on March 9, 2026, subject to customary conditions.
• ·Notes mature on April 1, 2031; redeemable after April 6, 2029 under specific conditions.
• ·Initial conversion rate: 3.5825 shares per $1,000 principal amount.

06-03-2026

Pattern Group Inc. (PTRN) reported strong revenue growth of 39.3% YoY to $2.5B in 2025 from $1.8B in 2024, with cost of goods sold up 39.0% and sales & marketing expenses rising 46.8%. However, profitability declined sharply as net income fell to $16.2M from $67.9M, operating income dropped to $25.4M from $87.2M, and operating margin compressed to 1.0% from 4.9% amid higher operating expenses reaching 99.0% of revenue. Adjusted EBITDA improved to $152.9M from $100.7M, supported by a $104.3M share-based compensation charge and a $32.7M stock amendment expense.

• ·Net cash provided by operating activities increased to $99.4M in 2025 from $70.3M in 2024.
• ·Net cash used in investing activities doubled to $39.8M in 2025 from $20.4M in 2024.
• ·Net cash provided by financing activities swung to $53.7M inflow in 2025 from $2.9M outflow in 2024.
• ·2025 provision (benefit) for income taxes was ($17.0M) compared to $23.4M in 2024.
• ·2023 Adjusted EBITDA was $64.7M and net income $41.3M.

06-03-2026

Guidewire Software reported strong H1 FY26 revenue growth of 25% YoY to $692M, driven by 32% increase in subscription and support revenue to $459M, achieving net income of $91M versus a $28M loss in H1 FY25. However, license revenue remained essentially flat at $101M YoY for H1 and declined 7% in Q2, while services showed negative gross profit in Q2; cash and equivalents dropped $290M to $408M amid investing outflows and $148M stock repurchases. Total assets slightly declined to $2.69B from $2.72B.

• ·Operating cash flow increased to $44.6M from $23.7M YoY for H1.
• ·Stock-based compensation expense $90.1M for H1 FY26 vs $79.0M prior.
• ·Business acquisition for $33.3M net of cash in H1 FY26.
• ·Convertible senior notes net $676.3M as of Jan 31, 2026.

06-03-2026

Jade Biosciences reported $336.2M in cash, cash equivalents, and investments as of December 31, 2025, up significantly from $69.4M at year-end 2024, following $180M in private placement proceeds, providing runway into H1 2028. Pipeline advances include JADE101 Phase 1 interim data in Q2 2026, Phase 2 initiation mid-2026, JADE201 first-in-human in Q2 2026, and JADE301 nomination with Phase 1 in H1 2027. However, R&D expenses rose 62% QoQ to $28.5M in Q4 2025 and 198% YoY to $93.1M for FY2025, G&A increased 167% QoQ to $6.4M and 374% YoY to $20.4M, driving net loss up 6% QoQ to $31.9M and 171% YoY to $127.4M.

• ·Total assets $349.8M as of Dec 31, 2025 (vs $72.8M Dec 31, 2024)
• ·Total liabilities $17.3M as of Dec 31, 2025 (down from $119.6M Dec 31, 2024)
• ·Stockholders’ equity $332.5M as of Dec 31, 2025 (vs deficit of $46.8M Dec 31, 2024)
• ·Company inception date June 18, 2024

06-03-2026

Genesco Inc. reported Q4 FY26 net sales of $800M, up 7% YoY from $746M, with comparable sales +9% driven by Journeys (+12%), while full-year FY26 sales rose 5% to $2.4B with comp sales +6%; operating income increased 11% to $51.3M in Q4 and 24% to $17.3M for the year on an adjusted basis. However, gross margins declined 100bps to 45.9% in Q4 and 90bps adjusted for FY26 due to promotions at Schuh and tariff pressures at Genesco Brands, with Brands sales down 27% in Q4 and 4% FY, Johnston & Murphy flat FY sales, and FY27 outlook showing total sales down 1% to flat despite 1-2% comp growth.

• ·E-commerce sales 31% of retail sales in Q4 FY26 (vs 30% prior), 25% FY26 (flat YoY).
• ·6 stores opened and 15 closed in Q4 FY26; net 42 store closings FY26.
• ·FY27 guidance: adj EPS $1.90-$2.30; tax rate ~30% (7-8% first three quarters due to valuation allowance).
• ·No share repurchases in Q4 FY26.

06-03-2026

Western Alliance Bancorporation disclosed a material non-cash impairment charge of $126.4 million on March 2, 2026, due to counterparties breaching a commercial loan facility and forbearance agreement by failing to make a required $42.125 million principal payment and discontinuing future payments. The outstanding loan balance is $126.4 million, with the charge to be recognized in Q1 2026. The Bank has asserted claims and will pursue legal remedies for recovery, though outcomes remain uncertain amid forward-looking risks.

• ·Filing date: March 6, 2026
• ·Date of earliest event: March 2, 2026
• ·Securities: Common Stock (WAL), Depositary Shares WAL PrA on NYSE

06-03-2026

Prudential Financial, Inc.'s subsidiary, The Prudential Gibraltar Financial Life Insurance Co., Ltd. (PGFL), issued a press release on March 6, 2026, disclosing instances of unauthorized removal of information by certain PGFL employees seconded to financial institutions in Japan. The Company furnished an English translation of the press release as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. No financial impacts or further details on the scope of the incident were provided.

• ·Filing signed by Brian P. Spitser, Vice President and Assistant Secretary.

06-03-2026

AgEagle Aerial Systems Inc. (dba EagleNXT, NYSE: UAVS) announced a strategic investment in Israel's Aerodrome Group Ltd., a developer of precision loitering munitions, to boost capabilities in autonomy and precision strike technologies. The investment includes a reserved right for EagleNXT to establish a U.S.-based joint venture, subject to mutual agreement and regulatory approvals. This aligns with EagleNXT's mission in uncrewed systems for defense and other sectors, with CEO Bill Irby highlighting its role in enhancing security and operational effectiveness.

• ·EagleNXT’s platforms achieved FAA approvals for Operations Over People (OOP) and Beyond Visual Line of Sight (BVLOS)
• ·EASA C2 certification in Europe
• ·Inclusion on the U.S. Department of Defense’s Blue UAS list
• ·Forward-looking statements subject to risks including investment success and regulatory approvals for joint venture

06-03-2026

NextTrip, Inc. (NTRP) announced on March 6, 2026, that it signed an agreement with J. Bradley Hilton’s Hilton Advisory Group to accelerate its premium wellness travel products across JOURNY.tv and Five Star Alliance. The press release is furnished under Item 7.01 (Regulation FD Disclosure) as Exhibit 99.1 and includes forward-looking statements regarding future performance.

• ·Filing includes Exhibit 99.1: Press Release dated March 6, 2026
• ·Registrant details: Nevada incorporation, Commission File Number 001-38015, IRS EIN 27-1865814, address 3900 Paseo del Sol, Santa Fe, New Mexico 87507

06-03-2026

Adial Pharmaceuticals reported FY2025 financial results with cash and equivalents at $5.9M (up from $3.8M in FY2024), a reduced net loss of $8.0M (vs. $13.2M prior year, improved ~39%), R&D expenses down 19% ($609K decrease), but G&A expenses up 2% ($125K increase). The company advanced AD04 regulatory progress including positive FDA feedback and EOP2 meeting, expanded IP with patents through 2045, secured partnerships like Cytel and Genomind, U.S. manufacturing with Cambrex/Thermo Fisher, and a framework for $60M Europe deal with Molteni, while regaining Nasdaq compliance. Cash is projected to fund operations into H2 2026.

• ·Nasdaq compliance regained on Feb 24, 2026 (notice Feb 23, 2026), matter now closed.
• ·Molteni collaboration framework announced March 3, 2026, subject to definitive agreement.
• ·International patent application for AD04 published Jan 14, 2026 (filed July 2024), potential protection to 2045.
• ·Six-figure milestone payment received from Adovate on May 13, 2025 for Phase 1 trial of ADO-5030.

06-03-2026

Stanley Black & Decker's 2026 Proxy Statement discloses no related party transactions since the start of fiscal 2025 and details non-employee director compensation for 2025, including an annual cash retainer of $125,000, annual RSUs valued at $200,000 (up from $185,000), and additional retainers for committee chairs and roles like Lead Independent Director ($45,000 aggregate RSUs). Total 2025 compensation ranged from $20,408 (prorated for new/short-term directors) to $649,955 (Andrea J. Ayers), with aggregate equity grant fair value of $1.76M; major shareholders include Vanguard (12.0%) and insiders own less than 1%. Human capital strategy is overseen by the CEO and CHRO, with annual talent reviews presented to the Board.

• ·No related party transactions requiring disclosure since beginning of fiscal 2025.
• ·Ownership data as of February 25, 2026; director changes include Laschinger joining November 1, 2025, Poul retiring at 2025 Annual Meeting.
• ·Chief Human Resources Officer (CHRO) reports to CEO; annual talent reviews with Compensation Committee and full Board.

06-03-2026

Clover Health Investments, Corp. (CLOV) published written responses to a selection of frequently asked supplemental shareholder questions related to its fourth quarter 2025 earnings announcement on March 6, 2026. The Q&A is furnished as Exhibit 99.1 to this Form 8-K and available on the company's investor relations website. This disclosure is pursuant to Regulation FD and not deemed 'filed' for purposes of the Exchange Act.

• ·Related to fourth quarter 2025 earnings announcement.
• ·Securities registered: Class A Common Stock, par value $0.0001 per share (CLOV).
• ·Remote-first company with no physical headquarters; communications to secretary@cloverhealth.com.

06-03-2026

Servier announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) for $21.50 per share in cash, representing a total equity value of approximately $2.5B, a 68% premium over the March 5, 2026 closing price and 86% over the one-month VWAP. The transaction, which positions Servier as a leader in pediatric low-grade glioma and expands its oncology pipeline, is expected to close in Q2 2026 subject to customary conditions including majority tender and U.S. antitrust clearance. No financial declines or flat metrics reported, though forward-looking statements highlight risks such as failure to meet closing conditions.

• ·Servier invests nearly 20% of brand-name sales in R&D
• ·Day One Board recommends shareholders tender shares
• ·Advisors: Baker McKenzie (Servier legal), Fenwick & West LLP (Day One legal)

06-03-2026

Marriott Vacations Worldwide Corporation announced that Executive Vice President and General Counsel James Hunter will transition from his role on March 9, 2026, and retire on April 1, 2026, after nearly 20 years of service, including key roles in expansions, the 2011 spin-off from Marriott International, and the 2018 merger with ILG. CEO Matt Avril expressed thanks for Hunter's contributions in building teams and industry leadership, noting he will remain in an advisory role through retirement to ensure a smooth transition. The announcement highlights the company's 120 vacation ownership resorts and approximately 700,000 owner families.

• ·Hunter began in-house legal career at Marriott International in 1994, supporting global development in Asia-Pacific.
• ·Relocated to Orlando in 2006 to lead Law Department of Marriott Vacation Club International.
• ·Hunter will assume presidency of Florida Citrus Sports in April 2026.

06-03-2026

Honeywell announced that Honeywell Aerospace Inc. has launched a private offering of up to $16B in senior notes and entered into $3B five-year and $1B 364-day revolving credit facilities to finance the planned spin-off of Aerospace, expected in Q3 2026. Proceeds from New Money Notes will fund a cash distribution to Honeywell and related fees, while Exchange Notes settle prior debt obligations. However, the offering size, timing, and terms are subject to market conditions, with significant risks including potential delays, failure to complete the spin-off, or lack of anticipated benefits.

• ·Notes offered only to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S
• ·Notes guaranteed by Honeywell until Spin-Off completion, after which guarantees are automatically released
• ·Closing of Notes offering not contingent on Spin-Off completion

06-03-2026

Chilean Cobalt Corp. amended its binding earn-in and option agreement with NeoRe SpA on March 2, 2026, clarifying the NeoRe Rare Earth Project properties at 6,300 hectares across 21 mining concessions without altering financial terms. The company issued a press release announcing land expansion by 2,100 hectares through 7 new concessions, initial drilling of 192 meters with intercepts up to 1,060 ppm TREE and surface samples over 800 ppm, and an accelerated program targeting Tranche 1 completion by July 2026. Exploration has identified over 20 additional targets, with ongoing metallurgical testing of more than 100 samples supported by University of Concepción and CORFO.

• ·Amendment filed March 6, 2026, references prior 8-K on January 14, 2026.
• ·Drilling transition to execution phase with two parallel crews planned.
• ·Conceptual engineering initiated for modular processing including crushing and milling circuit.
• ·CORFO award supports analytical and metallurgical work.

06-03-2026

Escalade Incorporated appointed Patrick J. Griffin as full-time Chief Executive Officer and President on March 5, 2026, transitioning from his interim role held since October 29, 2025. Mr. Griffin, previously Vice President of Corporate Development and Investor Relations and a Director since August 2012, has no family relationships with other executives or material interests in transactions under Regulation S-K. No changes were made to his compensation from the offer letter dated November 10, 2025.

• ·Mr. Griffin, age 56, previously served as President of Martin Yale Group, a former Escalade subsidiary, and in various roles since 2002.
• ·Additional details in Form 10-K for year ended December 31, 2025, and proxy statement filed March 28, 2025.

06-03-2026

Broadridge Financial Solutions, Inc. declared a quarterly cash dividend of $0.975 per share, payable on April 8, 2026, to stockholders of record at the close of business on March 16, 2026. The announcement was made via press release on March 6, 2026.

• ·Filing date: March 6, 2026
• ·Record date: March 16, 2026
• ·Payment date: April 8, 2026

06-03-2026

On February 28, 2026, Lynn Stockwell was removed as Chief Executive Officer, Executive Chair, and Board member due to the Sponsor's improper withdrawals totaling $1.1M from working capital post-IPO, including a $566k overpayment that was not returned despite Board demands. Roger Bendelac was appointed as the new CEO effective the same date, with compensation to be determined later. The incident highlights governance issues but ensures leadership continuity.

• ·Sponsor withdrawals occurred between IPO completion on September 26, 2025, and September 30, 2025 ($1.1M), with additional overpayment adjustments through December 31, 2025.
• ·Board directed Sponsor to return full overpayment on February 12, 2026; Stockwell agreed to resign on February 18, 2026.
• ·Roger Bendelac, 69, has over 30 years in investment banking; no family relationships or related party transactions with the Company.

06-03-2026

On February 28, 2026, Lynn Stockwell was removed as Chief Executive Officer, Executive Chair of the Board, and Board member of Drugs Made In America Acquisition Corp. following issues with the sponsor of its affiliate, Drugs Made In America Acquisition II Corp., which improperly withdrew $1.1M from the affiliate's working capital account between September 26 and September 30, 2025, including a $566,269 overpayment and at least $200,000 more for unrelated expenses. Roger Bendelac was appointed as the new CEO effective the same date, with compensation to be determined later. The resignations stem from the sponsor's inability to repay overpayments as directed on February 12, 2026.

• ·Sponsor withdrawals from affiliate occurred between completion of affiliate's IPO on September 26, 2025, and September 30, 2025; additional withdrawals between September 30, 2025, and December 31, 2025.
• ·Affiliate Board directed sponsor to return full overpayment on February 12, 2026; learned on same date sponsor unable to repay.
• ·Stockwell agreed to resign on February 18, 2026, at request of both Company and Affiliate Boards; resignation effective February 28, 2026 upon receipt.

06-03-2026

Independent Bank Corporation's DEF 14A proxy statement for the 2026 Annual Meeting on April 21, 2026, seeks shareholder approval to elect four directors (Terance L. Beia, Stephen L. Gulis Jr., William B. Kessel for three-year terms expiring 2029; Michael G. Wooldridge for one-year term expiring 2027), ratify Crowe LLP as auditors for FY 2026, and advisory votes on executive compensation and frequency. As of the February 20, 2026 record date, 20,769,374 common shares were outstanding, with no performance metrics reported but major 5%+ beneficial owners disclosed including BlackRock (9.0%), Vanguard (6.4%), and FMR LLC (5.0%). Board size is fixed at 10 members.

• ·Annual Meeting: April 21, 2026 at 3:00 p.m. ET, virtual at www.virtualshareholdermeeting.com/IBCP2026
• ·Record date: February 20, 2026
• ·Michael G. Wooldridge appointed to Board in December 2025
• ·Notice of Internet Availability mailed on or about March 6, 2026

06-03-2026

Republic Bancorp, Inc. reported robust 2025 financial results, with net income surging 30% YoY to $131.3M, diluted EPS up 29% to $6.72, ROA improving 25% to 1.84%, and ROE rising 17% to 12.31%, fueled by net interest income growth to $334.7M (up 7% YoY) and NIM expansion to 5.05% from 4.85%. Average interest-bearing deposits grew 6% or $203M, with costs declining to 2.26% from 2.67%, reducing interest expense by 10% or $9.6M. However, the Traditional Bank booked a $4.8M specific provision on a $16M C&I participation loan in Q4 2025 amid borrower revenue declines and expense pressures, while TRS Refund Advances and Other RPG loans saw average balances decrease.

• ·Noninterest-bearing deposits average balance declined $42.6M YoY to $1.33B in 2025.
• ·Allowance for credit losses stable at approx. $92M in 2025 vs 2024.
• ·Stockholders’ equity average grew to $1.07B in 2025 from $965M in 2024.

06-03-2026

FIRST FINANCIAL BANKSHARES INC (FFIN) filed its DEF 14A proxy statement for the 2026 annual shareholder meeting on April 28, 2026, at 10:30 a.m. CT in Abilene, Texas, with a record date of March 2, 2026. Shareholders are asked to vote on Proposal 1: election of directors; Proposal 2: ratification of independent auditors; and Proposal 3: advisory vote on named executive officer compensation, including detailed 2025 compensation discussion and analysis with equity awards data for PEO and Non-PEO NEOs across years 2021-2025. No specific financial performance metrics or period-over-period changes are detailed in the visible content.

• ·Annual meeting location: Abilene Convention Center, 1100 North 6th Street, Abilene, Texas.
• ·RSVP for post-meeting luncheon required by April 15, 2026, via phone 325.627.7038 or email awatkins@ffin.com.
• ·Live video stream available at www.ffin.com/live-events; replay post-event.
• ·Proxy materials available at www.ffin.com/sec.

06-03-2026

Peoples Bancorp Inc. (PEBO) filed its DEF 14A proxy statement for the virtual annual shareholder meeting on April 23, 2026, at 10:00 a.m. EDT, with a record date of February 23, 2026. Key proposals include electing eleven directors for one-year terms expiring at the 2027 meeting, an advisory vote to approve named executive officers' compensation as disclosed, and ratification of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. No financial performance metrics or period-over-period comparisons are detailed in the filing excerpt.

• ·Meeting held solely via live webcast at www.proxydocs.com/pebo; no in-person attendance.
• ·Shareholder proposals for 2027 annual meeting must be received by December 2026 (specific date not provided in excerpt).

06-03-2026

Camden National Corporation reported net income of $65.2M for 2025, up 23% YoY from $53.0M in 2024, fueled by the January 2, 2025 acquisition of Northway Financial, Inc., which drove net interest income to $203.3M (+53% YoY) and total assets to $6.97B (+20% YoY). However, non-interest expenses surged 38% YoY to $154.8M due to $9.3M in merger costs, return on average equity declined slightly to 9.96% from 10.36%, and tangible book value per share dipped to $29.69 from $29.91. Adjusted metrics reflected stronger results, including adjusted net income of $74.4M (+39% YoY) and adjusted return on average tangible equity of 17.27%.

• ·Dividends declared per share remained flat at $0.42 quarterly across all quarters in 2025 and 2024.
• ·Adjusted pre-tax, pre-provision income increased to $109.6M in 2025 from $66.2M in 2024.
• ·Non-GAAP efficiency ratio improved to 54.46% in 2025 from 62.05% in 2024.

06-03-2026

ArcelorMittal's total sales declined 1.7% YoY to $61.4B in 2025 from $62.4B in 2024, driven by drops in Brazil (-9.9%), Europe (-3.9%), and Sustainable Solutions (-2.1%), despite gains in Mining (+21.4%) and North America (+3.7%). Operating income rose 9.6% YoY to $3.6B, with strong growth in North America (+68.3%), Sustainable Solutions (+149.1%), and Europe (+35.2%), but offset by a sharp decline in Brazil (-56.5%) and flat Mining performance (+2.5%). North America saw crude steel production up 2.9% to 7.8M tonnes, though long product shipments fell 4.3%.

• ·North America flat product shipments: 8,378 thousand tonnes (+4.4% YoY)
• ·North America long product shipments: 2,378 thousand tonnes (-4.3% YoY)
• ·North America average steel selling price: $1,014/tonne (+2.9% YoY)
• ·North America total steel shipments: 10,283 thousand tonnes (+2.2% YoY)

06-03-2026

Northrim Bancorp reported net income of $64.6M for 2025, surging 75% YoY from $37.0M in 2024, fueled by net interest income growth of 20% to $135.6M and other operating income jump of 84% to $77.2M, while assets expanded 8% to $3.29B and ROE rose to 21.7% from 14.7%. However, nonperforming loans increased to $11.3M (0.49% of portfolio) from $7.5M (0.35%), provision for credit losses rose 19% to $3.9M, and other operating expenses grew 16% to $122.1M. Dividend per share increased slightly to $0.64 from $0.62.

• ·Five-year compound growth rate for net income: 14%
• ·Tangible book value per share: $12.47 (2025) vs $9.79 (2024)
• ·Allowance for credit losses to portfolio loans stable at 1.03% (2025 and 2024)
• ·Total employees grew 3% over five years to 516 FTE
• ·Common shares outstanding five-year CAGR: -2%

06-03-2026

Great Southern Bancorp, Inc. reported net income of $71M for the year ended December 31, 2025, up 15% YoY from $62M in 2024, driven by a 6% increase in net interest income to $200M and no provision for credit losses on loans. However, total assets declined 6% YoY to $5.6B, net loans receivable fell 7% to $4.4B, and deposits decreased 3% to $4.5B amid higher interest expense pressures. Non-performing assets improved 15% to $8.1M (0.14% of average total assets), while foreclosed assets ticked up slightly to $6.0M.

• ·Tier 1 capital ratio for Great Southern Bancorp, Inc. at 14.1% as of Dec 31, 2025 (up from 12.8% in 2024).
• ·Efficiency ratio improved to 61.91% in 2025 from 64.40% in 2024.
• ·Subordinated debentures balance stable at $25.8M across 2023-2025.
• ·Average subordinated notes balance declined sharply to $34.1M in 2025 from $74.7M in 2024.

06-03-2026

The 2026 Proxy Statement for First Bancorp, Inc. (FNLC) details governance practices, including the Audit Committee's financial expertise led by independent Chair F. Stephen Ward, procedures for related party transactions exceeding $120,000 (none in 2025 except ordinary loans of $28.3M to directors/executives, or 1.21% of total loans), and no adopted written policy but established review processes. Director compensation from the Bank totaled $291,100 in 2025, with 54% reinvested via stock purchase plan and no fees paid to the Company for directorships. Executive officer bios highlight long tenures and recent promotions/appointments in 2025-2026.

• ·Director fees structure: Chair $44,600 annual; others $1,400 monthly retainer, $1,050 per board meeting, $700 per committee meeting.
• ·Code of Business Conduct and Ethics re-approved Sept 25, 2025; available on investor website.
• ·Internal audits outsourced except loan review; Bank regulated by OCC, FDIC, Federal Reserve.
• ·Ms. Kachmar joined Board Feb 2025; several executives promoted Feb 2025.

06-03-2026

ArcBest provided preliminary Q1 2026 (Jan-Feb) operating trends under Regulation FD, with Asset-Based segment showing +1% YoY billed revenue/day QTD driven by +6% tonnage/day but offset by flat shipments/day, -1% revenue/shipment, and -5% revenue/CWT; Asset-Light segment reported +6% revenue/day and +13% shipments/day YoY but -7% revenue/shipment and purchased transportation at 87% of revenue. Expectations include Asset-Light non-GAAP operating income up to $2M (excluding $3M purchase accounting amortization) and Asset-Based operating ratio rising 100-200 bps sequentially versus historical 260 bps seasonality.

• ·January 2026 had 20.5 workdays vs 22.0 in January 2025, while February had 20.0 workdays both years.
• ·Asset-Based February tonnage/day +2% YoY driven by +2% weight/shipment, but revenue/CWT -2%.
• ·Asset-Light February shipments/day +12% YoY led by Managed, but revenue/shipment -3%.
• ·Asset-Based sequential from Jan to Feb: shipments/tonnage +1%, revenue/shipment +2%.
• ·Asset-Light sequential from Jan to Feb: revenue/day +10%, shipments +7%, revenue/shipment +3%.

06-03-2026

Unity Bancorp, Inc. (UNTY) filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of Shareholders on April 23, 2026, held virtually at 8:00 A.M. local time via meetnow.global/MCJW47X. The proxy solicits votes for the election of five director nominees (George Boyan, Wayne Courtright, David D. Dallas, Robert H. Dallas, Peter E. Maricondo) and ratification of Wolf & Company, P.C. as independent auditors for the year ending December 31, 2026, with the Board recommending FOR all proposals. No financial performance data or period comparisons are included in the materials.

• ·Proxy holders: James A. Hughes and George Boyan
• ·Voting options: Online at www.investorvote.com/UNTY, phone 1-800-652-VOTE (8683), or mail

06-03-2026

GT Biopharma reported no revenues for the three and nine months ended September 30, 2025, with R&D expenses decreasing 51% YoY to $0.6M and 46% to $2.1M respectively in the three and nine-month periods, while SG&A rose 20% YoY to $2.7M in Q3 but fell 30% YoY to $4.7M YTD, leading to improved operating losses of $3.4M (-6% smaller) and $6.8M (-36% smaller). However, non-operating items including a $28.7M loss on Greenshoe Rights initial recognition drove a Q3 net income of $8.3M but a larger nine-month net loss of $22.6M (worsened 141% YoY); cash and equivalents declined to $2.5M from $4.0M at year-end 2024 amid $8.9M operating cash burn.

• ·Stock-based compensation included $379K in Q3 2025 SG&A (vs $0 in 2024) and $386K YTD 2025 (vs $222K 2024).
• ·Current liabilities decreased to $1.3M at Sep 30, 2025 from $5.9M at Dec 31, 2024.
• ·Total assets stable at $4.3M Sep 30, 2025 vs $4.2M Dec 31, 2024; stockholders' equity turned positive to $3.0M from -$1.7M.
• ·Financing activities provided $7.5M net cash nine months 2025 (vs $3.0M 2024), including $6.5M from Series L preferred issuance.
• ·Net cash decrease of $1.4M nine months 2025; operating cash burn improved to $8.9M from $10.4M YoY.

06-03-2026

Pantages Capital Acquisition Corporation entered into a Business Combination Agreement on November 18, 2025, with MacMines Austasia Pty Ltd, Horizon Mining Limited (Pubco), and others, pursuant to which a merger sub will merge with Purchaser, surviving as a wholly-owned subsidiary of Pubco, with Purchaser's securities converting into Pubco Ordinary Shares subject to redemptions. The agreement includes customary conditions to closing such as board resignations, no material adverse effects, and compliance with covenants, with termination possible by mutual consent or March 31, 2026 if conditions are unmet. Concurrent agreements include a Seller Lock-Up for 50% of securities until 6 months post-closing or $12.50/share threshold, support agreements from Seller and Sponsor, and planned Registration Rights.

• ·Merger Agreement signed November 18, 2025; outside date for termination March 31, 2026.
• ·Seller Lock-Up period: from Closing until earliest of 6-month anniversary or $12.50/share for 20 trading days in 30-day period.
• ·Securities traded as PGACU (Units), PGAC (Class A Ordinary Shares), PGACR (Rights) on Nasdaq.
• ·No fractional Pubco Ordinary Shares issued; rounded down to nearest whole share.

06-03-2026

Black Spade Acquisition III Co, a SPAC incepted on August 21, 2025, reported total assets of $3.7M as of December 31, 2025, driven by $3.3M in cash, but offset by $3.7M in liabilities including $3.3M in related party advances. The company incurred a net loss of $86k from general and administrative costs, leading to a shareholders' deficit of $61k despite issuing 5.75M Class B ordinary shares for $25k. No Class A shares are issued, and operations remain pre-business combination with ongoing offering costs.

• ·Basic and diluted net loss per Class B ordinary share: $0.02
• ·Accrued offering costs: $282k
• ·Accrued expenses: $43k
• ·Deferred offering costs: $384k
• ·Audited by PCAOB ID#100 firm

06-03-2026

Banc of California, Inc. filed a new universal shelf registration statement on Form S-3 (File No. 333-293930) on March 2, 2026, which became effective immediately and replaced the prior 2023 shelf registration (File No. 333-270328). On March 6, 2026, the Company filed a prospectus supplement for the resale of shares of its voting common stock by certain selling stockholders, as required by the Registration Rights Agreement dated November 30, 2023. A legal opinion from Silver, Freedman, Taff & Tiernan LLP was included as Exhibit 5.1.

• ·2023 Registration Statement filed March 7, 2023 (File No. 333-270328)
• ·Prior prospectus supplement filed March 1, 2024 under 2023 Registration Statement
• ·Registration Rights Agreement dated November 30, 2023

06-03-2026

Athena Bitcoin's global Bitcoin ATM deployments declined 5% YoY from 3,111 in 2024 to 2,953 in 2025, while the overall ATM market grew modestly from 37.7 thousand to 39.2 thousand machines, with Australia showing the strongest regional growth at 43%. Global cryptocurrency owners rose 12.4% YoY to 741 million in 2025, driven by Ethereum owners (+22.6% to 175 million), though Bitcoin owners grew more slowly at 8.3% to 365 million.

• ·Athena Bitcoin, Inc. owns 99% of Athena Holdings El Salvador S.A. de C.V. (Eric Gravengaard holds 1% on behalf of company).
• ·Athena Bitcoin, Inc. beneficially owns Athena Holdings Colombia SAS (nominally Eric Gravengaard 95%, Matias Goldenhörn 5%).
• ·Australia added 600 Bitcoin ATMs (fastest growth).
• ·Potential 300,000 to 1.2 million additional people invested in BTC via US spot ETFs.
• ·Historical Athena Bitcoin ATMs: 65 (2017), 445 (2022), 1,829 (2023).

06-03-2026

Bridger Aerospace Group Holdings, Inc. reported FY2025 revenues of $122.8M, up 25% YoY from $98.6M, with strong growth in aerial surveillance (+33%), MRO (+54%), and fire suppression (+20%), though other services declined 16%. The company achieved net income of $4.1M, reversing a $15.6M loss, with Adjusted EBITDA up 21% to $45.3M from $37.3M; however, SG&A expenses were flat at up 1%, cash and equivalents fell to $31.4M from $39.3M due to investing outflows, and loss attributable to common stockholders improved to $22.9M but remained negative with EPS of -$0.42.

• ·Net cash provided by operating activities increased to $16.7M in FY2025 from $9.4M in FY2024.
• ·Net cash used in investing activities was $34.4M in FY2025 vs provided $2.1M in FY2024.
• ·Total liabilities rose to $265.6M as of Dec 31, 2025 from $237.3M.
• ·Stockholders’ deficit widened to $342.6M from $326.7M.
• ·Revenues from Spain grew 39% YoY to $14.0M, while US revenues up 23% to $108.8M.

06-03-2026

Kratos Defense & Security Solutions, Inc. completed its acquisition of Orbit Technologies Ltd. on March 2, 2026, via a merger, acquiring 100% of Orbit's ordinary shares for approximately $352.7 million in cash funded from its balance sheet, at $13.725 per share. Orbit, previously publicly traded on the Tel Aviv Stock Exchange, is now an indirect wholly owned subsidiary of Kratos. No financial impacts or performance metrics were disclosed in this filing.

• ·Merger Agreement dated November 4, 2025, previously disclosed in 8-K filed November 7, 2025
• ·Orbit ordinary shares delisted from Tel Aviv Stock Exchange post-merger
• ·All outstanding Orbit options fully vested and canceled for cash payment based on Merger Consideration

06-03-2026

FirstSun Capital Bancorp's 2025 net income rose 29.5% YoY to $97.9M from $75.6M, supported by net interest income growth of 6.9% to $317.4M and noninterest income up 13.4% to $101.9M, while total assets expanded 4.8% to $8.5B and deposits grew 6.5% to $7.1B. However, noninterest expenses increased 2.9% to $271.8M, provision for credit losses of $24.6M remained elevated above 2023's $18.2M, net charge-offs rose to 0.43% from 0.32%, and key profitability ratios like ROE at 8.88% and NIM at 4.10% trailed 2023 levels of 12.50% and 4.23%, respectively.

• ·No cash dividends declared or paid in 2025, 2024, or 2023.
• ·Merger related expenses net of tax: $2.6M in 2025 (down from $9.9M in 2024).
• ·Total risk-based capital ratio: 15.73% in 2025 (up from 15.42% in 2024).
• ·Loan to deposit ratio declined to 93.9% in 2025 from 95.6% in 2024.
• ·Allowance for credit losses to loans: 1.27% in 2025 (down from 1.38% in 2024).

06-03-2026

On March 3, 2026, AGCO Corporation's Talent and Compensation Committee approved amendments to the 2026 Annual Incentive Plan, updating individual award opportunities, performance metrics, and their weightings to align with current program design. The changes eliminate individual award limits, broaden adjustment provisions for the committee's discretion, and add recoupment under clawback policies, reflecting legal updates post-repeal of Section 162(m) exceptions. No specific financial impacts or performance data were disclosed.

• ·Amendments qualified by reference to Exhibit 10.1 (full Plan text)
• ·Plan designated as management contract or compensation plan

06-03-2026

Federal Signal Corporation's DEF 14A proxy statement outlines the Annual Meeting on April 21, 2026, to elect eight directors (reducing board size from nine, with Dennis J. Martin not standing for re-election), approve advisory vote on NEO compensation, and ratify Deloitte & Touche LLP as independent auditors for FY 2026. The record date is February 23, 2026, with 60,892,151 common shares outstanding. All director nominees are current directors, and the Board recommends voting 'FOR' all proposals.

• ·Annual Meeting location: 1333 Butterfield Road, Suite 500, Downers Grove, IL 60515 at 8:30 a.m. CDT.
• ·Proxy materials first mailed March 6, 2026 via Notice of Internet Availability at www.proxyvote.com.
• ·Messrs. Maue and Vaillancourt appointed as directors on February 26, 2026.

06-03-2026

Rogers Communications Inc filed its 40-F annual report for FY2025 ended December 31, 2025, detailing operations across Wireless, Cable, and Media segments with year-over-year comparisons to FY2024 and FY2023. The filing discloses the MLSE Transaction on July 1, 2025, involving Maple Leaf Sports & Entertainment Ltd., including assets classified as held for sale, property, plant & equipment, intangibles, and depreciation details. Equity structure includes Class A Voting Shares and Class B Non-Voting Shares, with notes on credit facilities like the Canada Infrastructure Bank Credit Facility due 2052; no specific performance improvements or declines quantified.

• ·Filing date: March 06, 2026
• ·Reporting period: January 1, 2025 to December 31, 2025
• ·Comparative periods: FY2024 (2024-01-01 to 2024-12-31) and FY2023
• ·MLSE Transaction date: July 1, 2025
• ·Disposal groups classified as held for sale: December 2025
• ·Credit facilities include Canada Infrastructure Bank Credit Facility Due 2052, Revolving Credit Facility 1, Accounts Receivable Securitization Program

06-03-2026

On March 3, 2026, Waste Management, Inc.'s Management Development and Compensation Committee granted performance share units (PSUs), stock options, and annual cash incentive awards to its named executive officers, including CEO James C. Fish, Jr., under the 2023 Stock Incentive Plan. PSU grants ranged from 7,272 to 49,350 units per executive, tied to cash flow generation (50%) and relative TSR vs. S&P 500 (50%), with payouts from 0-200% as of December 31, 2028; stock options ranged from 8,405 to 57,034 shares at $241.55 exercise price, vesting over three years. Annual cash incentives target base salary percentages, based on 2026 operating EBITDA, margin, and revenue growth, adjustable by up to 10% via sustainability scorecard and 25% via committee discretion.

• ·PSU performance period ends December 31, 2028, with payout after committee certification.
• ·Stock options have 10-year term; vesting: 34% year 1, 33% year 2, 33% year 3.
• ·Annual cash incentives require employment through December 31, 2026, except for death (prorated).
• ·Detailed termination provisions for PSUs and options include full payout on death/disability post-2026 retirement, forfeiture on cause termination.

06-03-2026

Equity Bancshares Inc reported net income of $22.7M for 2025, down 64% YoY from $62.6M in 2024, driven by a $53.2M net loss on securities transactions and higher merger expenses of $8.1M, resulting in ROAA declining to 0.40% from 1.23%. However, net interest income rose 22% to $226.1M on 20% loan growth to $4.20B and total assets expanding 20% to $6.37B, with deposits up 17% to $5.14B. Core diluted EPS remained stable at $4.39, while capital ratios stayed strong but ticked lower, with CET1 at 13.08%.

• ·Shares outstanding: 20,992,139 Class A Common Stock (Feb 27, 2026); 0 Class B.
• ·Equity compensation plans available for future issuance: 1,040,294 securities.
• ·Provision for credit losses: $9.0M in 2025 vs $2.5M in 2024.
• ·Common Equity Tier 1 Capital Ratio: 13.08% (2025) vs 14.51% (2024).
• ·Efficiency ratio stable at 60.90% (2025) vs 60.77% (2024).

06-03-2026

IPG Photonics Corporation filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025, solely to correct the cover page disclosure regarding incorporation by reference to its proxy statement for the 2026 Annual Meeting; no changes were made to financial statements or other disclosures from the original filing on February 23, 2026. The amendment includes new Section 302 certifications but omits others as no financials are revised. Aggregate market value of non-affiliate common stock was approximately $1.8B as of June 30, 2025, with 42,191,353 shares outstanding as of February 20, 2026.

• ·Registrant is a large accelerated filer.
• ·Proxy statement for 2026 Annual Meeting to be filed within 120 days of December 31, 2025.

06-03-2026

Curanex Pharmaceuticals Inc (CURX) entered into employment agreements effective March 1, 2026, with CEO and President Jun Liu (annual base salary $393,600 plus $3,998 monthly car lease) and COO Dr. Liqin Xie (annual base salary $180,000), formalizing their continuing roles since February 2024 and June 2024, respectively. Both agreements provide eligibility for equity incentives, employee benefits, and 3-month salary continuation plus accelerated vesting upon termination without cause or for good reason. The CEO agreement has an initial 4-year term, renewable annually by mutual consent.

• ·CEO Jun Liu originally appointed to CEO and President roles in February 2024.
• ·COO Dr. Liqin Xie originally appointed on June 17, 2024.
• ·Agreements entered on March 2, 2026; CEO term ends on fourth anniversary unless terminated earlier.
• ·Both agreements include non-compete, non-disclosure, non-solicitation covenants and require Proprietary Information and Invention Assignment Agreement.

06-03-2026

Medalist Diversified REIT, Inc.'s subsidiary, MDR Ashley Plaza, LLC, entered into a Purchase and Sale Agreement on March 5, 2026, to sell the 156,012 square foot Ashley Plaza retail property in Goldsboro, North Carolina, for total consideration of $16.6M, subject to prorations and adjustments. The purchaser, HPX Goldsboro Ashley Center LLC, must provide earnest money deposits totaling $300k. The transaction is expected to close within 90 days, though several conditions remain unsatisfied and there is no assurance of completion.

• ·Property address: 201–221 North Berkeley Boulevard, Goldsboro, North Carolina
• ·Closing expected within 90 days of March 5, 2026, subject to customary conditions, representations, warranties, covenants, and indemnities

06-03-2026

Home Bancorp, Inc. reported net income of $46.1M for the year ended December 31, 2025, up 26% YoY from $36.4M, with diluted EPS increasing to $5.87 from $4.55 and ROA improving to 1.33% from 1.08%. Total assets grew 1.4% to $3.49B, deposits rose 6.9% to $2.97B, and net interest income increased 10.8% to $133.3M. However, asset quality deteriorated sharply with non-performing loans jumping to 1.25% of total loans from 0.50% and non-performing assets rising to 1.03% of total assets from 0.45%, while loans grew only 0.9% YoY.

• ·Provision for loan losses was $1.1M in 2025, down from $2.4M in 2024.
• ·Shareholders’ equity increased to $435.1M as of Dec 31, 2025 from $396.1M.
• ·Tier 1 risk-based capital ratio strengthened to 14.09% from 13.28%.
• ·Cash dividends per share rose to $1.14 in 2025 from $1.01.

06-03-2026

Greenidge reported preliminary Q4 2025 total revenue of $11.5M, down $3.7M or ~24% QoQ from Q3, with cryptocurrency mining revenue declining $1.6M and datacenter hosting down $3.0M, though power and capacity revenue improved $0.8M; net income fell to $1.9-2.9M QoQ. For FY2025, revenue was $58.8M, down $0.8M or ~1% YoY from FY2024, with mining revenue down $3.8M and bitcoin production down 570 to 371, but net income improved to $4.2-5.2M, power revenue rose $11.4M, and debt was reduced to $39M. The company secured 100MW of future power capacity and a Title V Air Permit renewal for the Dresden facility, supporting AI/HPC transition.

• ·Secured 60MW non-curtailable power at Dresden facility and 40MW at Mississippi greenfield site by Q1 2027.
• ·Initiated NYISO study for additional 200MW at Dresden.
• ·Agreement with NYSDEC for Dresden permit renewal post-public comment, extending C-Pond closure to Oct 2027.
• ·Senior unsecured debt reduced from $157.5M in 2023 and $68.5M at FY2024 end to $39M.
• ·SG&A expenses reduced from $26.1M in 2023 to $12.1M in FY2025.

06-03-2026

Medicus Pharma Ltd. disclosed sales of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under the Standby Equity Purchase Agreement (SEPA) dated February 10, 2025, for total consideration of $3,846,910 across multiple transactions from December 19, 2025, to March 6, 2026. Part of the net proceeds were used to prepay a portion of an outstanding debenture with Yorkville. The shares were issued pursuant to the Section 4(a)(2) exemption from registration.

• ·SEPA dated February 10, 2025; sales occurred on specific dates including December 19, 2025 (71,099 shares for $122,868), December 29, 2025 (62,159 shares for $98,600), January 9, 2026 (100,000 shares for $150,640), and others up to March 6, 2026.
• ·Prepayment of debenture referenced in prior 8-K dated September 18, 2025.
• ·Yorkville may resell shares under an effective registration statement filed by the Company.

06-03-2026

InMed Pharmaceuticals Inc. ratified the wind down of its wholly-owned subsidiary BayMedica LLC's commercial operations, the company's sole revenue-generating segment, due to H.R. 5371 legislation effective November 12, 2026, with completion targeted by fiscal year-end June 30, 2026. This will incur approximately $550,000 in severance and employee costs plus $120,000 in other expenditures, partially offset by interim sales profits. Pro forma financials for six months ended December 31, 2025, eliminate $1.94M in sales and $587k gross profit but reduce operating expenses, resulting in a slightly narrower continuing operations loss of $3.91M versus the as-filed total; for FY 2025, continuing loss widens to $8.47M after removing $4.94M sales and $1.71M gross profit.

• ·H.R. 5371 effective November 12, 2026, prohibiting aspects of BayMedica's cannabinoid business.
• ·BayMedica to continue limited operations until fiscal year-end June 30, 2026.
• ·Pro forma cash decreases by $215K to $6.74M as of Dec 31, 2025; inventories and receivables eliminated.

06-03-2026

Boeing's 2026 DEF 14A Proxy Statement discloses 2025 compensation for named executive officers (NEOs), with CEO Robert K. Ortberg receiving total pay of $23.6M, up 28% from $18.4M in 2024, driven by $9.6M in option awards and $3.9M incentive pay. Other NEOs like Stephanie F. Pope saw total comp rise 44% to $14.4M from $10.0M, while new CFO Jesus Malave, Jr. earned $20.2M including an $8.5M bonus; however, stock option grants to NEOs in February 2025 occurred amid a 3.8% decline in share price following material nonpublic information disclosure. The filing reaffirms robust clawback and insider trading policies with no interlocks or excessive risk in comp design.

• ·No stock options granted to NEOs during blackout periods around 10-K/10-Q/8-K filings except specified Feb 2025 grants.
• ·Clawback policy adopted June 27, 2023, applies to incentive comp earned on/after Oct 2, 2023.
• ·No Compensation Committee interlocks in 2025; independent review by FW Cook confirms no excessive risk in comp programs.

06-03-2026

On March 5, 2026, Midland States Bancorp, Inc. terminated Eric Lemke from his position as Chief Financial Officer of the Company and its subsidiary Midland States Bank, with no specified reason provided. The Company promptly appointed Claire Stack, age 37 and previously Corporate Controller since November 2025, as Vice President – Chief Accounting Officer and interim CFO, leveraging her 15+ years of accounting and finance experience. A Change of Control Agreement was entered with Ms. Stack, offering severance of 150% of salary plus average prior three-year bonuses upon qualifying termination post-change of control, though the CFO departure raises potential governance concerns.

• ·Claire Stack joined as Corporate Controller in November 2025; holds BS in Accounting and Technology Management from Indiana University’s Kelley School of Business; Certified Public Accountant (CPA).
• ·Change of Control Agreement initial term through December 31, 2026; auto-renews annually unless 90 days' nonrenewal notice; post-termination non-compete/non-solicit for 12 months; COBRA coverage up to 12 months on qualifying termination.
• ·Agreement form filed as Exhibit 10.4 to 2025 Form 10-K.

06-03-2026

Global Mofy AI Ltd filed an F-3 shelf registration statement on March 6, 2026, enabling potential future offerings of securities without specific amounts or uses detailed at this time. The company reports authorized share capital of $1.02M, divided into 30B Class A ordinary shares and 4B Class B ordinary shares, each with a par value of $0.00003. As of the prospectus date, 45.8M Class A shares and 5.7M Class B shares are outstanding, with Class B shares carrying 20 votes per share compared to 1 vote for Class A.

• ·Incorporated as a Cayman Islands exempted company on September 29, 2021.
• ·Former name: Global Mofy Metaverse Ltd (changed February 25, 2022).
• ·Class A Ordinary Shares: 1 vote per share; Class B Ordinary Shares: 20 votes per share.
• ·SEC file number: 333-294113.

06-03-2026

Civista Bancshares reported net income of $46.2M for 2025, up 46% YoY from $31.7M in 2024, driven by net interest income growth of 19% to $138.6M and net interest margin expansion to 3.61% from 3.21%, with total assets reaching $4.34B. However, noninterest income declined 10% YoY to $34.0M amid lower lease revenue, while noninterest expenses remained flat at $113.9M, and net income remained below 2023's $43.0M peak. The company completed the Farmers Savings Bank acquisition, issuing shares worth $31.2M.

• ·Diluted EPS $2.64 in 2025, up from $2.01 in 2024 but below $2.73 in 2023
• ·Provision for credit losses $3.4M in 2025, down from $5.4M in 2024
• ·Common dividends $0.68 per share in 2025, up from $0.64
• ·Shareholders’ equity $543.5M at Dec 31, 2025, up 40% from $388.5M in 2024
• ·Noninterest-bearing deposits flat at $702M end-2025 vs $695M end-2024

06-03-2026

DigitalBridge Group, Inc. filed a preliminary proxy statement (PREM14A) dated March 6, 2026, for a special online stockholder meeting to approve the merger with Duncan Holdco LLC pursuant to an Agreement and Plan of Merger dated December 29, 2025, under which DigitalBridge will survive as a wholly owned subsidiary following the merger of Merger Sub I with DigitalBridge and Merger Sub II with DigitalBridge Operating Company, LLC. The DigitalBridge Board unanimously recommends voting FOR the merger proposal, FOR the non-binding advisory vote on named executive officer merger-related compensation, and FOR the adjournment proposal if needed to solicit more votes. Dissenting stockholders have appraisal rights under Maryland law.

• ·Merger agreement attached as Annex A; opinions of Barclays Capital Inc. (Annex B) and J.P. Morgan Securities LLC (Annex C); appraisal rights detailed in Annex D.
• ·Proxy solicitor contact: 800-676-7437 (toll-free) or 212-931-0845 (banks/brokers).
• ·Special meeting to be held online; record date [•], 2026.